New WHO report: 100 million people affected by psoriasis, action needed to provide care, overcome discrimination. - Providing training for health professionals, especially in primary care settings; - Developing standardised guidelines for the diagnosis of psoriasis and its treatment; - Empowering people with psoriasis…
Dec 17, 2021, 17:20 ET SILVER SPRING, Md., Dec. 17, 2021 /PRNewswire/ -- The U.S. Food and Drug Administration today approved Vyvgart (efgartigimod) for the treatment of generalized myasthenia gravis (gMG) in adults who test positive for the anti-acetylcholine receptor (AChR) antibody. Vyvgart is the first approval of…
"'How could this work?' we asked ourselves," said Caspi. "Scientists are like little kids, when they get an answer to one question, there is immediately the next level of 'why?' So we started looking at the deeper mechanisms that make…
Monthly ianalumab reduced systemic disease activity in Sjögren’s disease, but symptom improvements remained limited. Ianalumab Lowers Disease Activity in Sjögren’s Disease, Though Symptom Benefits Remain Unclear Patients with active Sjögren’s disease treated with monthly ianalumab experienced significantly greater reductions in…
A small population of immune cells carrying changes in a gene called STAT3 may contribute to some autoimmune diseases, researchers at Australia’s Garvan Institute of Medical Research have found. The 2022 study offers a possible explanation for a connection seen in some…
Dry eye disease was often recorded before an autoimmune disease diagnosis in a large study of medical records from Taiwan. Among patients who had both diagnoses, dry eye was typically recorded about three years earlier. The finding was especially striking…
Results from the global Phase 3 ALKIVIA study, the first registrational study investigating an FcRn blocker in autoimmune myositis, show efgartigimod provides clinically meaningful improvements in IMNM and DM Patient improvements observed as early as Week 4 and sustained through 52 weeks Late-breaking…
October 8, 2026, 7:00 AM CET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology innovation company, today announced that it will discontinue the Phase 3 UNITY study of efgartigimod subcutaneous (SC) (efgartigimod alfa and hyaluronidase-qvfc) in adults with moderate-to-severe Sjögren's disease.
ZILBRYSQ is the first and only macrocyclic peptide C5 inhibitor approved as a self-administered once-daily, subcutaneous autoinjector for adults living with generalized myasthenia gravis (gMG) in the U.S.¹ ZILBRYSQ now offers two self-administration options for adults living with gMG who are anti-acetylcholine…
Older age and lower baseline FVC independently predicted worse outcomes. Each 5-year increase in age was associated with a 15% higher risk of death or lung transplantation (HR, 1.15), while each 5-percentage-point increase in predicted FVC was associated with a 9% lower risk…
Autoimmune diseases in general: why women get them more often, myasthenia gravis and rarer conditions, research and CAR-T resets of the immune system.
An article joins this feed when it matches these terms. Each one is also a search of its own.